• EN

    • -+ 0.00%
    -+ 0.00%
    -+ 0.00%

    Vaxcyte Stock Gets A Lift From Strong Vaccine Trial Results

    Simply Wall St·11/06/2026 08:25:04
    Listen to the news
    • Vaxcyte reported third quarter 2026 results with a net loss of US$297.06 million and basic loss per share of US$1.99, while also highlighting positive topline OPUS-1 Phase 3 data for its VAX-31 pneumococcal vaccine candidate in adults.
    • The combination of deeper losses and a pivotal VAX-31 trial that met all primary endpoints, with a safety profile similar to existing pneumococcal conjugate vaccines, captures the central trade off between heavy investment and potential future franchise building for Vaxcyte.
    • We will examine how Vaxcyte's investment narrative is reshaped by OPUS-1's endpoint success and safety readout for the adult VAX-31 program.

    Compare Vaxcyte's high-spend, high-upside profile with other potential healthcare contenders by scanning our hand picked 34 healthcare AI stocks, which are also leaning into data and drug development breakthroughs.

    Vaxcyte Investment Narrative Recap

    To own Vaxcyte, you need to be comfortable with a pure execution story. The business is still pre revenue and is running sizable losses, with a third quarter net loss of US$297.06 million and nine month loss of US$901.99 million. The short term upside arguably hinges on clean readouts from the remaining VAX-31 adult and infant studies and on staying on track for the planned BLA submission.

    The recent OPUS-1 success supports that near term catalyst, since it speaks directly to VAX-31 efficacy and safety in adults. The flip side is the steep cash burn and rising R&D and manufacturing spend, which could accelerate as late stage trials and commercial scale buildout intensify. If costs run hotter than expected or timelines slip, financing risk becomes the key operational overhang.

    The OPUS-1 Phase 3 announcement is the disclosure that matters most here. Management reported that VAX-31 met all primary endpoints in adults with a safety profile similar to existing pneumococcal conjugate vaccines. For a pre revenue vaccine developer, that type of readout directly supports the future Biologics License Application and the broader thesis that VAX-31 can move from clinic toward potential commercialization.

    Where this connects back to catalysts is timing and reliability. OPUS-2 and OPUS-3 adult trials and the infant VAX-31 program still carry clinical and regulatory risk, and the firm is committing significant capital to US manufacturing capacity. Investors are essentially weighing strong initial adult VAX-31 data and progress on VAX-A1 against ongoing losses, share dilution over the past year and the possibility that future guideline or competitive shifts could limit eventual uptake.

    Vaxcyte's narrative projects US$748.4 million revenue and US$119.1 million earnings by 2029. This implies a move from zero revenue today, along with an earnings increase of about US$1.2 billion from the current earnings level of a US$1.1 billion loss.

    Uncover why Vaxcyte's fair value indicates an 89% potential upside to its current price, which could materialize faster than many investors expect.

    NasdaqGS:PCVX 1-Year Stock Price Chart
    NasdaqGS:PCVX 1-Year Stock Price Chart

    Exploring Other Perspectives

    Some of the most optimistic analysts lean hard into market size as the swing factor for Vaxcyte. Before this OPUS-1 update, they were mapping the roughly US$8.5b to US$12b pneumococcal space onto forecasts like US$521.1m in 2029 revenue and about US$95.3m in earnings. That is far more upbeat than the baseline consensus and could shift again once fresh trial and cash burn data are fully absorbed.

    Explore 2 other Vaxcyte fair value estimates, including one that suggests as much as 190% upside from the current price.

    Decide For Yourself

    Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so trust your own analysis.

    Looking For More Investment Ideas Beyond Vaxcyte?

    If the Vaxcyte story has sharpened your thinking on risk, reward and execution, it can help to line it up against other opportunities using a structured stock filter.

    • For investors hunting for potential mispricing with quality in mind, scan a curated set of 42 high quality undervalued stocks. These pair fundamentals with more modest expectations baked into their prices.
    • If capital preservation sits higher on your priority list, focus on resilience and balance sheet strength by starting with a 32 resilient stocks with low risk scores. These already screen well on financial stability metrics.
    • For those searching for lesser known opportunities with robust underlying data, broaden your watchlist with a 21 high quality undiscovered gems. These combine strong fundamentals with relatively low market attention.